drugset / Trial / NCT02815839

Single Dose Study of SHR4640 in Healthy Subjects

NCT02815839

Phase 1 Completed 50 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to assess the safety, tolerance, food effect, pharmacokinetic and pharmacodynamic properties of single dose adminstration of SHR4640 in healthy volunteers.

Timeline

Start
2015-11
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR4640 Small molecule 2.5 mg
Subject SHR4640 Small molecule 5 mg
Subject SHR4640 Small molecule 7.5 mg
Subject SHR4640 Small molecule 10 mg
Subject SHR4640 Small molecule 20 mg

Indications